PRP

PRP is often described with one persuasive sentence: “We use your own blood to regenerate your skin or hair.”

There is some truth in that description, but it compresses several important clinical questions into one attractive idea.

Platelet-rich plasma is prepared from the patient’s own blood. Blood is collected and processed so that a plasma fraction containing a higher concentration of platelets can be separated and then used in the intended treatment area.

Platelets contain signalling molecules involved in wound healing and tissue repair. That biological fact is why PRP has attracted interest across surgery, sports medicine, dermatology and aesthetic medicine.

But PRP is not one standard drug manufactured to one universal concentration. Different preparation systems can produce very different platelet concentrations, leukocyte content, plasma volumes and activation characteristics.

This means I do not think the useful question is simply, “Does PRP work?”

I want to know something more precise: what are we treating, what PRP preparation are we actually producing, and is the evidence strong enough for that particular indication to justify the injections?

PRP is a blood-derived preparation, not a stem-cell treatment

This distinction should be clear from the beginning.

Platelets are blood components involved in haemostasis and tissue repair. They release several growth factors and signalling molecules after activation.

They are not stem cells.

The fact that PRP can influence repair pathways does not make it equivalent to stem-cell therapy, and the presence of growth factors does not mean new tissue can be generated without biological limits.

I think the terminology matters because regenerative medicine is especially vulnerable to words being allowed to imply more than the treatment has demonstrated.

PRP can provide biological signals.

A signal is not the same thing as a guarantee that the tissue will regenerate in the way we want.

That distinction gives us a much better basis for discussing both skin and hair treatment.

There is no single universal PRP in the syringe

Two clinics can both say they are performing PRP while preparing biologically different products.

The blood volume collected can differ. Centrifugation speed and duration can differ. Some preparation systems use one spin and others use two. The final platelet concentration can differ significantly. Leukocytes may be retained or reduced. The final plasma volume can differ, which changes the concentration of the material delivered.

Some protocols activate the platelet preparation before injection. Others rely on activation occurring within the tissue.

These differences are one reason PRP research is difficult to compare.

If one study demonstrates a useful response with one processing protocol, I cannot automatically assume that every commercial tube labelled PRP will reproduce the same biology.

Standardisation is not an academic detail here.

It determines what treatment the patient actually receives.

The fact that PRP is autologous is an advantage, not proof of efficacy

Because PRP comes from the patient’s own blood, the risk of an immune reaction to a foreign filler material is fundamentally different.

That is a genuine advantage.

But “it comes from your own body” is sometimes used as though it simultaneously proves safety and effectiveness.

It does neither by itself.

The patient’s own blood can still be processed poorly. Sterility still matters. Injection technique still matters. The wrong diagnosis remains the wrong diagnosis even when the injected material is autologous.

Likewise, a substance does not become effective for every aesthetic concern merely because the body produced it.

Autologous tells me where the material came from.

It does not tell me whether this patient needs it.

PRP for hair loss begins with the diagnosis of hair loss

Hair is probably the aesthetic indication in which PRP has generated the greatest sustained clinical interest.

But “hair loss” is still not one disease.

Androgenetic alopecia behaves differently from acute diffuse shedding after illness or major stress. Alopecia areata is another mechanism again. Scarring alopecias can permanently damage follicles and require medical diagnosis and disease control. Nutritional, endocrine and medication-related factors may also contribute to shedding.

If I inject the scalp before understanding which process is occurring, PRP has replaced diagnosis rather than followed it.

The best evidence for scalp PRP is around androgenetic alopecia, where systematic reviews and randomised trials suggest that PRP can improve hair density in selected patients.

The evidence is encouraging.

It is also heterogeneous.

Preparation methods, treatment intervals and outcome measurements vary substantially between studies, which is why I do not translate a positive average result into a guarantee for every patient.

Hair density and complete hair restoration are very different promises

This is where expectation language matters.

A patient with miniaturising but still viable follicles may have biological tissue that can respond to supportive treatment.

An area that has been completely bald for a long period may contain very different follicular potential.

PRP does not manufacture an unlimited number of new follicles.

It also does not change the genetic susceptibility driving androgenetic alopecia.

Supporting a follicle that is still biologically present is different from recreating a follicle that is no longer functioning.

This is why I position scalp PRP as a possible supportive treatment in appropriately diagnosed hair loss rather than as an injectable hair transplant.

PRP should not automatically replace established hair-loss treatment

Patients sometimes prefer PRP because it feels more natural than medication.

That preference is understandable.

But treatment choice should still follow evidence and diagnosis.

For androgenetic alopecia, established medical treatments can have an important role. PRP may be used as an adjunct in selected patients rather than requiring the patient to choose between “natural PRP” and “medical treatment”.

The two approaches do not work through identical mechanisms.

If a patient is obtaining useful disease control from an established treatment, discontinuing it simply because injections feel more regenerative can undermine the overall plan.

I prefer to ask what PRP adds to the strategy rather than what it can replace for marketing simplicity.

Scalp PRP also has to be judged on a hair-growth timeline

Hair biology is slow.

A treatment performed today cannot be judged intelligently by the appearance of the scalp next week.

Hair growth cycles operate over months, and normal shedding fluctuates. Hair length, styling, colour, lighting and the way the hair is parted can all make density photographs look different without a real change in follicular number.

This means assessment has to be disciplined.

Standardised photographs and, when available, reproducible density measurements are much more useful than asking whether the patient thinks the hair “looks fuller” under different lighting.

The timeline also gives us permission to wait.

Performing another injection prematurely does not accelerate the biological clock of the follicle.

PRP for facial rejuvenation has a more uncertain evidence base

PRP is also widely injected into facial skin or used alongside microneedling and laser resurfacing.

The proposed logic is plausible: platelet-derived signals may influence fibroblast activity, extracellular matrix remodelling and wound healing.

Clinical studies have reported improvements in texture, fine wrinkles, elasticity and patient satisfaction.

But when the literature is reviewed as a whole, the certainty is much less impressive than the marketing language.

Many studies are small. Some are uncontrolled. PRP preparation is inconsistent. Different outcomes are measured, and PRP is frequently combined with another treatment such as laser or microneedling, making it difficult to know how much of the improvement belongs to the PRP itself.

I therefore consider facial PRP promising rather than universally proven.

That is not the same thing as saying it does nothing.

It means the confidence of the claim should match the quality of the evidence.

“Vampire Facial” is a memorable name but a poor clinical definition

The term became popular because PRP is derived from blood and can be applied or injected during facial treatment.

But the nickname tells me almost nothing about what actually happened.

Was PRP injected directly?

Was it applied after microneedling?

Was it combined with fractional laser resurfacing?

How was the PRP prepared?

How deeply was the accompanying procedure performed?

Those differences are clinically much more important than the commercial name.

I prefer to describe the actual intervention rather than make the blood itself the spectacle.

PRP combined with microneedling needs a reason for both components

Microneedling already creates controlled mechanical injury and initiates wound healing.

PRP can then be added with the intention of modifying or supporting that healing response.

This combination has biological logic, and some clinical studies report better outcomes with combined treatment than with microneedling alone for selected indications.

But combination treatment still needs to answer a simple question: what additional benefit are we expecting from the PRP?

If the patient’s problem is mild enough that microneedling alone is likely to provide the required improvement, adding another treatment component is not automatically more sophisticated.

If PRP is being used because evidence suggests it may improve recovery or treatment outcome in the specific context, that is a much stronger justification.

Combination treatment should add a mechanism, not merely add a name.

The same applies when PRP is combined with laser resurfacing

A resurfacing laser creates the principal structural injury.

That controlled injury is what drives much of the remodelling response.

PRP may be used as an adjunct with the intention of influencing healing, recovery or the quality of the subsequent tissue response.

Again, this does not mean every laser treatment becomes better when PRP is automatically added.

The evidence varies according to laser type, treatment indication and PRP protocol.

I want the patient to understand which treatment is carrying the main corrective mechanism and which treatment is supportive.

Otherwise the contribution of each intervention becomes impossible to judge.

PRP is not structural filler

This distinction is especially important around the face.

PRP is sometimes presented using language such as “natural volumisation”.

That can be misleading.

Immediately after injection, the fluid itself and tissue swelling can create temporary fullness. That is not the same thing as durable structural volume replacement.

If the patient has a genuine cheek-volume deficiency or another contour problem, PRP does not become a hyaluronic-acid filler simply because it was injected into the same anatomical region.

Likewise, it does not reposition descended tissues.

A treatment designed to support skin quality should be judged as a skin-quality treatment.

PRP is not a substitute for a facelift because growth factors are involved

The language of regeneration can easily blur treatment categories.

Platelet-derived signalling can participate in tissue repair.

That does not mean the treatment reverses every anatomical component of ageing.

A jowl exists because of changes in support, soft-tissue position, skin and deeper facial anatomy. Significant upper-eyelid skin excess is another structural problem. A deep tear trough may involve volume and ligamentous anatomy.

PRP cannot reposition those structures through biological signalling alone.

The correct category remains important even when the treatment sounds regenerative.

PRP preparation quality is part of the treatment

With a manufactured medication, the physician receives a product whose formulation has already been standardised.

PRP is prepared at the point of care.

That means collection, anticoagulation, centrifugation, transfer and sterility all become part of the clinical procedure.

If the preparation is inconsistent, the dose being delivered is inconsistent.

If sterility is compromised, the fact that the original blood belonged to the patient does not protect them from infection.

I therefore consider the preparation system and protocol as important as the injection technique.

The syringe does not become medically simple because its contents started in the patient’s own vein.

The platelet count should not become a competition

It is tempting to assume that more platelets must produce a better treatment.

Biology rarely behaves that linearly.

There may be ranges in which platelet concentration influences the biological activity of the preparation, but the ideal composition can vary according to tissue and indication.

Extremely concentrated preparations are not automatically clinically superior.

The presence or absence of leukocytes may also change the inflammatory characteristics of a preparation.

This is another reason I do not judge PRP quality simply by the largest multiplication factor printed on a kit.

A laboratory number needs clinical context.

Pain and bruising are modest concerns compared with getting the indication wrong

PRP treatment commonly involves multiple injections.

Temporary pain, tenderness, redness, swelling and bruising can occur. Scalp injections can be uncomfortable because relatively large areas may be treated through multiple punctures.

Infection is uncommon when proper sterile technique is used but remains possible.

Patients with relevant blood disorders, platelet abnormalities, active infection or certain medical conditions and medications may require modification or avoidance of treatment depending on the clinical situation.

But the most common conceptual risk is simpler.

A patient can undergo several technically perfect PRP sessions for a problem that PRP was never likely to solve.

Correct indication remains the first layer of safety.

A fixed three-session package is not a diagnosis

Many PRP protocols use an initial series.

That can be reasonable because both hair and skin outcomes may require repeated treatment and adequate observation time.

What I resist is treating the number of sessions as though it defines PRP itself.

Different indications have different biology. Different PRP systems have different protocols. The patient response matters.

If the scalp is responding and the treatment remains appropriate, continuing a planned course may make sense.

If there has been no meaningful biological signal after an adequate assessment period, repeating the same injections indefinitely is not evidence-based persistence.

It is failure to reassess.

Maintenance should follow the mechanism that remains

PRP does not freeze the biology of hair or skin.

Androgenetic alopecia can continue progressing. Skin continues ageing. Environmental damage continues accumulating.

A patient who obtains useful improvement may therefore choose further treatment later.

But the reason for repeating treatment should be visible again.

If hair density remains stable, another injection is not automatically required because a calendar reminder has appeared.

If the face has developed a new structural ageing problem, repeating PRP because it once helped skin quality may be irrelevant to the new concern.

Maintenance should preserve benefit.

It should not preserve the treatment habit.

What a good PRP result means to me

For androgenetic hair loss, I look for a clinically meaningful improvement or stabilisation in density and hair quality within the limits of the patient’s follicular potential and overall treatment plan.

For skin, I expect subtler outcomes.

Texture may become somewhat more even. Fine surface changes may improve. The patient may perceive better skin quality, particularly when PRP is used within an appropriately selected combination treatment.

I do not expect PRP to reconstruct a lost facial structure.

I do not expect it to create new hair follicles where no viable follicular system remains.

And I do not use the word regeneration to hide those limitations.

The treatment should be judged by what the evidence and tissue biology allow it to achieve.

When PRP makes sense to me

I am most comfortable recommending PRP when the problem is clearly defined and there is a credible evidence base for using platelet-derived biological signalling in that context.

Androgenetic alopecia is one of the more coherent aesthetic indications, particularly when PRP is positioned as part of a broader hair-loss strategy rather than a guaranteed cure.

Facial skin treatment can also be considered in selected patients, but I use a more cautious evidence threshold and keep the expected result modest.

I become less enthusiastic when PRP is being sold primarily because it is “natural”, when the preparation method is poorly defined, when a structural problem is being relabelled as a regenerative one, or when several previous sessions have produced no meaningful result.

PRP is biologically interesting.

That is not enough.

The treatment becomes clinically useful only when the preparation, the diagnosis and the expectation all belong to the same problem.

Frequently asked questions

What exactly is PRP?

Platelet-rich plasma is an autologous blood-derived preparation produced by processing a patient’s blood to obtain plasma containing a higher concentration of platelets than baseline whole blood.

Is PRP stem-cell therapy?

No. Platelets contain growth factors and signalling molecules involved in repair, but platelets are not stem cells. PRP and stem-cell-based treatments are biologically and clinically different categories.

Does PRP work for hair loss?

The strongest aesthetic evidence is for androgenetic alopecia, where studies suggest PRP can improve hair density in selected patients. The evidence remains heterogeneous, and the result depends on diagnosis, preparation protocol and individual follicular biology.

Can PRP regrow hair on a completely bald area?

I would not promise that. PRP is most coherent when viable follicles remain. It does not reliably recreate an absent follicular population or replace hair transplantation when transplantation is the appropriate structural solution.

Can PRP replace minoxidil or other hair-loss treatments?

Not automatically. Established treatments and PRP work through different mechanisms and can sometimes be used together. The underlying diagnosis should determine whether PRP is an adjunct, an alternative or not useful.

Does PRP rejuvenate facial skin?

Some studies report improvement in texture, fine lines and patient satisfaction, but systematic reviews describe the overall evidence as heterogeneous and often low certainty. I therefore keep facial rejuvenation claims conservative.

Does PRP add facial volume?

Not in the way structural filler does. Temporary swelling can create early fullness, but PRP should not be considered a substitute for a treatment whose purpose is to create projection or restore significant structural volume.

Why are PRP results different between clinics?

Preparation systems can differ in platelet concentration, leukocyte content, centrifugation protocol, final volume and activation. Treatment indication and injection method also vary, so the term PRP does not describe one completely standardised product.

Is more concentrated PRP always better?

No. A higher platelet count is not automatically equivalent to a better clinical outcome. Optimal biological composition can vary, and excessively simplified concentration claims ignore the rest of the preparation.

How many PRP sessions do I need?

There is no universal number for every indication. A staged initial protocol may be appropriate, but further treatment should depend on diagnosis, response and adequate time for the tissue to show that response.

Is PRP safe because it comes from my own blood?

Autologous origin reduces some material-related risks, but PRP still requires sterile preparation, appropriate injection technique and correct patient selection. Pain, bruising, swelling and infection are possible.

Can PRP be combined with microneedling or laser?

Yes, and some studies investigate those combinations. I prefer combination treatment only when PRP has a defined adjunctive role rather than being automatically added to every resurfacing procedure.

When would you recommend no PRP?

I would avoid or redirect treatment when the diagnosis is unclear, the proposed PRP preparation cannot be adequately characterised, the expected result requires structural correction, or an adequate previous treatment course has produced no meaningful benefit.